Evaxion will expand the use of its proprietary AI-Immunology platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas. “Autoimmune diseases can be severely debilitating and even lethal, placing a substantial burden on patients, their families and on society across all stages of life. With AI-Immunology we have a unique technology and a platform that we know can deliver new treatment opportunities. By expanding the platform into autoimmune diseases, we have the potential to meaningfully improve the outcome for patients and unlock significant partnership value from the platform,” says Helen Tayton-Martin, CEO at Evaxion.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion to Outline 2026 Milestones at Biotech Showcase in San Francisco
- Evaxion Retains Global Rights to Gonorrhea Vaccine EVX-B2 After MSD Declines Option
- Evaxion provides update on MSD collaboration, retains rights of EVX-B2
- Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million
- Evaxion Biotech: Innovative AI-Immunology Platform and Strategic Growth Potential Justify Buy Rating